ProImmune introduces ProStorm in vitro assay service

10:47 EDT 19 Sep 2012 | BioPortfolio

New service will enable drug developers to identify a potential risk of cytokine storm reactions for new therapeutics

Oxford, UK, 18 September 2012 – ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm™, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.  ProStorm™ offers drug developers an improved route to risk identification prior to initiating clinical trials in man.

Cytokine release syndrome (“cytokine storm”) is an acute immune reaction to first infusion of a drug, characterized by immediate release of proinflammatory cytokines. A lack of understanding of the risk of this reaction contributed to a near-fatal cytokine storm in participants in phase I clinical trials of TGN1412.  There is a clear need for preclinical assays such as ProStorm™ to assess the likelihood of this syndrome occurring.  If a potential risk is indicated, lower doses of the therapeutic can be used alongside prophylactic antihistamines or steroids to mitigate that risk.

ProStorm™ is designed specifically to indicate when a cytokine storm first infusion reaction may be a risk for a drug.  The ProStorm™ assay uses fresh undiluted whole blood from a large cohort of donors, to give a sensitive evaluation of cytokine responses to a therapeutic in one simple step. 

Dr. Nikolai Schwabe, CEO of ProImmune, said “First infusion cytokine storm reactions to new therapeutics can represent a substantial stumbling block to drug development.  Now, using the ProStorm™ assay service, developers of biologics can gain valuable information to inform the design of their first-in-man trials.  By offering ProStorm™, we at ProImmune are extending the range of services we offer to help our clients bring safe and effective therapeutics to market.”

For more information, please visit:


Notes to Editors:

About ProImmune -
ProImmune is a private biotechnology company that specializes in providing products and services for epitope discovery, antigen characterization, immune monitoring and the design of biological drugs with reduced immunogenicity and immunotoxicology risk. ProImmune has a wide range of customers, including leading pharmaceutical and biotechnology companies, as well as clinical and academic research institutes throughout the world.

For more information, please contact

At ProImmune:
Nikolai Schwabe, CEO
Tel: +44 (0) 870 042 7279

Media enquiries:
Sarah Jeffery
Zyme Communications Ltd
Tel: +44 (0) 7771 730 919
Twitter: zymecomms


More From BioPortfolio on "ProImmune introduces ProStorm in vitro assay service"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...